Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $24.6M | $45.6M | $54.5M | $38.2M | $49.1M | $71.3M | $88.5M |
| Revenue growth | — | 85.6% | 19.6% | -29.9% | 28.5% | 45.3% | 24.1% |
| Operating income | -$26.7M | -$22.9M | -$40.9M | -$50.6M | -$41.3M | -$34.5M | -$27.9M |
| Operating margin | -108.9% | -50.3% | -75.1% | -132.4% | -84.2% | -48.4% | -31.5% |
| Net income | -$30.7M | -$65.4M | -$43.2M | -$65.4M | -$52.1M | -$42.9M | -$35.3M |
| Net margin | -125.1% | -143.7% | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% |
| EPS (diluted) | -$126.97 | -$6.48 | -$1.58 | -$1.55 | -$0.64 | -$6.64 | -$4.67 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.7M | -$21.4M | -$28.2M | -$45.0M | -$22.9M | -$48.6M | -$23.3M |
| Capital expenditures | $1.31M | $1.95M | $2.24M | $3.30M | $22.9M | $3.23M | $259K |
| Free cash flow | -$23.0M | -$23.3M | -$30.5M | -$48.3M | -$45.8M | -$51.9M | -$23.5M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5.29M | $62.1M | $32.7M | $43.1M | $26.3M | $26.2M | $19.0M |
| Total assets | $45.0M | $121M | $76.1M | $92.9M | $99.1M | $97.2M | $87.5M |
| Total liabilities | $76.2M | $79.9M | $56.4M | $72.3M | $94.5M | $76.4M | $89.9M |
| Long-term debt | — | $28.1M | $10.1M | $30.1M | $40.1M | $40.0M | $50.0M |
| Shareholders' equity | -$225M | $41.2M | $19.7M | $20.6M | $4.58M | $20.9M | -$2.46M |
| Retained earnings | -$227M | -$259M | -$302M | -$367M | -$420M | -$462M | -$498M |
| Shares (wtd avg diluted) | 255K | 26.6M | 27.4M | 42.1M | 82.1M | 6.47M | 7.55M |
Every figure is extracted from BIODESIX INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.